Trial Profile

Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Bone metastases; Prostate cancer
Focus Biomarker; Therapeutic Use
Acronyms STARVE-PC

Most Recent Events

13 Oct 2021 Status changed from active, no longer recruiting to completed.
10 Apr 2020 Status changed from recruiting to active, no longer recruiting.
24 Sep 2019 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com